Topical Corticosteroids for Mycosis Fungoides

Zackheim, Herschel S.; Kashani‐Sabet, Mohammed; Amin, Smita

doi:10.1001/archderm.134.8.949

Cited by 209 publications

(104 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical corticosteroids produce both clinical and/or pathologic complete remissions in up to 63% of patients with limited patch/ plaque stage MF [205]. Nitrogen mustard (mechlorethamine) may be applied as an aqueous or ointment-based preparation and produces complete remissions in 50-75% of patients with limited patch/plaque stage disease [206,207].…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Topical corticosteroids have CR rates similar to other forms of SDTs. 22 Intralesional corticosteroids can be effective in treating thicker MF lesions, such as plaques or tumor deposits.…”

Section: Overviewmentioning

confidence: 99%

How I treat mycosis fungoides and Sézary syndrome

Prince

Whittaker

Hoppe

2009

Blood

136

109

View full text Add to dashboard Cite

The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a “stage-based” approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. Systemic approaches are used for recalcitrant early-stage disease, advanced-stage disease (IIB-IV), and transformed disease and include retinoids, such as bexarotene, interferon-α, histone deacetylase inhibitors, the fusion toxin denileukin diftitox, systemic chemotherapy including transplantation, and extracorporeal photopheresis. Examples of drugs under active investigation include new histone deacetylase inhibitors, forodesine, monoclonal antibodies, proteasome inhibitors, and immunomodulatory agents, such as lenalidomide. It is appropriate to consider patients for novel agents within clinical trials if they have failed front-line therapy and before chemotherapy is used.

show abstract

“…In an investigational trial, 79 patients were treated daily with topical class I-III steroids. 7 Thirtytwo patients (63%) of stage T1 patients and 7 (25%) of stage T2 patients achieved complete clearing. The duration of response depends on extent of disease and thickness of the targeted lesion.…”

Section: Steroidsmentioning

confidence: 96%

Primary Cutaneous T-Cell Lymphomas

Rosen¹,

Querfeld²

2006

Hematology

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphomas (CTCLs) encompass a clinically and biologically heterogeneous group of non-Hodgkin lymphomas (NHLs) defined by clonal proliferation of skin-homing malignant T lymphocytes and natural killer cells. They account for up to 75% to 80% of all cutaneous lymphomas. The current WHO-EORTC classification of cutaneous lymphomas with primary cutaneous manifestations lists 13 entities. The most common subtypes-mycosis fungoides, Clinical featuresMF is typically a chronic, slowly progressing disease with an indolent evolution. The disease is characterized by the development of patches, plaques or tumors (Figure 1; see Color Figures, page 513). The typical patch is a flat, annular, scaly skin lesion mimicking eczema, psoriasis, or dermatophyte infection. It is often erythematous to violaceous in color and has a predilection for sun-protected areas, including the lower abdomen, upper thighs, buttocks, and female breasts. These initial lesions may spontaneously regress and recur. Patches are highly variable and can give rise to or coexist with plaques, which are raised, palpable skin lesions (Figure 1a and 1b

show abstract

Topical Corticosteroids for Mycosis Fungoides

Cited by 209 publications

References 24 publications

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

How I treat mycosis fungoides and Sézary syndrome

Primary Cutaneous T-Cell Lymphomas

Contact Info

Product

Resources

About